203 related articles for article (PubMed ID: 6247744)
1. Manipulation of platelet aggregation by prostaglandins and their fatty acid precursors: pharmacological basis for a therapeutic approach.
Needleman P; Whitaker MO; Wyche A; Watters K; Sprecher H; Raz A
Prostaglandins; 1980 Jan; 19(1):165-81. PubMed ID: 6247744
[TBL] [Abstract][Full Text] [Related]
2. Triene prostaglandins: prostaglandin D3 and icosapentaenoic acid as potential antithrombotic substances.
Whitaker MO; Wyche A; Fitzpatrick F; Sprecher H; Needleman P
Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5919-23. PubMed ID: 230492
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors.
Rajtar G; Cerletti C; Castagnoli MN; Bertelé V; de Gaetano G
Biochem Pharmacol; 1985 Feb; 34(3):307-10. PubMed ID: 3918536
[TBL] [Abstract][Full Text] [Related]
4. Competitive antagonism at thromboxane receptors in human platelets.
Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
[TBL] [Abstract][Full Text] [Related]
5. Arachidonic acid induces human platelet-fibrin retraction: the role of platelet cyclic endoperoxides.
Di Minno G; Bertelé V; Cerletti C; de Gaetano G; Silver MJ
Thromb Res; 1982 Feb; 25(4):299-306. PubMed ID: 6803385
[TBL] [Abstract][Full Text] [Related]
6. Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties.
Needleman P; Raz A; Minkes MS; Ferrendelli JA; Sprecher H
Proc Natl Acad Sci U S A; 1979 Feb; 76(2):944-8. PubMed ID: 218223
[TBL] [Abstract][Full Text] [Related]
7. 9 alpha-homo-9,11-epoxy-5,13-prostadienoic acid analogues: specific stable agonist (SQ 26, 538) and antagonist (SQ 26, 536) of the human platelet thromboxane receptor.
Harris DN; Phillips MB; Michel IM; Goldenberg HJ; Heikes JE; Sprague PW; Antonaccio MJ
Prostaglandins; 1981 Aug; 22(2):295-307. PubMed ID: 6270744
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin endoperoxides, thromboxane A2 and adenosine diphosphate in collagen-induced aggregation of rabbit platelets.
Lewis GP; Watts IS
Br J Pharmacol; 1982 Apr; 75(4):623-31. PubMed ID: 6802211
[TBL] [Abstract][Full Text] [Related]
9. A selective thromboxane synthetase inhibitor blocks the cAMP lowering activity of PGH2.
Gorman RR; Fitzpatrick FA; Miller OV
Biochem Biophys Res Commun; 1977 Nov; 79(1):305-13. PubMed ID: 200243
[No Abstract] [Full Text] [Related]
10. A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid. Two selective thromboxane synthetase inhibitors.
Fitzpatrick FA; Gorman RR
Biochim Biophys Acta; 1978 Mar; 539(2):162-72. PubMed ID: 629996
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of the involvement of the prostaglandin H2/thromboxane A2 pathway in intravascular platelet aggregation in guinea-pigs and rats.
Mallarkey G; Smith GM
Br J Pharmacol; 1985 Feb; 84(2):425-30. PubMed ID: 3156648
[TBL] [Abstract][Full Text] [Related]
12. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders.
Gresele P; Blockmans D; Deckmyn H; Vermylen J
J Pharmacol Exp Ther; 1988 Jul; 246(1):301-7. PubMed ID: 3134542
[TBL] [Abstract][Full Text] [Related]
13. Familial bleeding tendency with partial platelet thromboxane synthetase deficiency: reorientation of cyclic endoperoxide metabolism.
Defreyn G; Machin SJ; Carreras LO; Dauden MV; Chamone DA; Vermylen J
Br J Haematol; 1981 Sep; 49(1):29-41. PubMed ID: 6268139
[TBL] [Abstract][Full Text] [Related]
14. Cyclic adenosine 3',5'-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions.
Minkes M; Stanford N; Chi MM; Roth GJ; Raz A; Needleman P; Majerus PW
J Clin Invest; 1977 Mar; 59(3):449-54. PubMed ID: 190267
[TBL] [Abstract][Full Text] [Related]
15. Thromboxane synthase inhibition causes re-direction of prostaglandin endoperoxides to prostaglandin D2 during collagen stimulated aggregation of human platelet rich plasma.
Orchard MA; Waddell KA; Lewis PJ; Blair IA
Thromb Res; 1985 Sep; 39(6):701-10. PubMed ID: 3936223
[TBL] [Abstract][Full Text] [Related]
16. Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation.
Smith JB; Araki H; Lefer AM
Circulation; 1980 Dec; 62(6 Pt 2):V19-25. PubMed ID: 7002350
[TBL] [Abstract][Full Text] [Related]
17. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
Bertele V; De Gaetano G
Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
[TBL] [Abstract][Full Text] [Related]
18. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
Watts IS; Wharton KA; White BP; Lumley P
Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
[TBL] [Abstract][Full Text] [Related]
19. Dihomogammalinolenic acid (20:3 omega 6) is more anti-aggregatory than eicosapentaenoic (20:5 omega 3) in a platelet-endothelial cell mixture.
Lagarde M; Burtin M; Dechavanne M; Sicard B; Coiffier B
Prostaglandins Med; 1980 Mar; 4(3):177-83. PubMed ID: 6248913
[TBL] [Abstract][Full Text] [Related]
20. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
